Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms

JAMA. 2003 Mar 5;289(9):1124-9. doi: 10.1001/jama.289.9.1124.

Abstract

Context: Despite more than 2 decades of outcomes research after very preterm birth, clinicians remain uncertain about the extent to which neonatal morbidities predict poor long-term outcomes of extremely low-birth-weight (ELBW) infants.

Objective: To determine the individual and combined prognostic effects of bronchopulmonary dysplasia (BPD), ultrasonographic signs of brain injury, and severe retinopathy of prematurity (ROP) on 18-month outcomes of ELBW infants.

Design: Inception cohort assembled for the Trial of Indomethacin Prophylaxis in Preterms (TIPP).

Setting and participants: A total of 910 infants with birth weights of 500 to 999 g who were admitted to 1 of 32 neonatal intensive care units in Canada, the United States, Australia, New Zealand, and Hong Kong between 1996 and 1998 and who survived to a postmenstrual age of 36 weeks.

Main outcome measures: Combined end point of death or survival to 18 months with 1 or more of cerebral palsy, cognitive delay, severe hearing loss, and bilateral blindness.

Results: Each of the neonatal morbidities was similarly and independently correlated with a poor 18-month outcome. Odds ratios were 2.4 (95% confidence interval [CI], 1.8-3.2) for BPD, 3.7 (95% CI, 2.6-5.3) for brain injury, and 3.1 (95% CI, 1.9-5.0) for severe ROP. In children who were free of BPD, brain injury, and severe ROP the rate of poor long-term outcomes was 18% (95% CI, 14%-22%). Corresponding rates with any 1, any 2, and all 3 neonatal morbidities were 42% (95% CI, 37%-47%), 62% (95% CI, 53%-70%), and 88% (64%-99%), respectively.

Conclusion: In ELBW infants who survive to a postmenstrual age of 36 weeks, a simple count of 3 common neonatal morbidities strongly predicts the risk of later death or neurosensory impairment.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Blindness / epidemiology
  • Brain Diseases / physiopathology*
  • Bronchopulmonary Dysplasia / physiopathology*
  • Cerebral Palsy / epidemiology
  • Cognition Disorders / epidemiology
  • Female
  • Gestational Age
  • Hearing Loss / epidemiology
  • Humans
  • Indomethacin / therapeutic use*
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases / epidemiology*
  • Infant, Premature, Diseases / physiopathology
  • Infant, Premature, Diseases / prevention & control*
  • Infant, Very Low Birth Weight*
  • Logistic Models
  • Male
  • Morbidity
  • Prognosis
  • Retinopathy of Prematurity / physiopathology*
  • Socioeconomic Factors
  • Survival Analysis

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Indomethacin